These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23195794)

  • 1. Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer.
    Blasinska-Morawiec M; Tubiana-Mathieu N; Fougeray R; Pinel MC; Bougnoux P
    Breast; 2013 Feb; 22(1):58-63. PubMed ID: 23195794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.
    Mansour M; Mourad C
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):429-35. PubMed ID: 23801283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinorelbine as first-line or second-line therapy for advanced breast cancer: a Phase I-II trial by the Danish Breast Cancer Co-operative Group.
    Langkjer ST; Ejlertsen B; Mouridsen H; Andersen J; Nielsen MM; Møller KA; Madsen EL; Haarh V;
    Acta Oncol; 2008; 47(4):735-9. PubMed ID: 18465342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
    Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
    J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer.
    Yardley DA; McCleod M; Schreiber F; Murphy P; Patton J; Thompson DS; Shastry M; Rubin M; Melnik M; Burris HA; Hainsworth JD
    Cancer Invest; 2010 Nov; 28(9):925-31. PubMed ID: 20690806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.
    Addeo R; Sgambato A; Cennamo G; Montella L; Faiola V; Abbruzzese A; Capasso E; Leo L; Botti G; Caraglia M; Del Prete S
    Clin Breast Cancer; 2010 Aug; 10(4):301-6. PubMed ID: 20705563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
    Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.
    Strada MR; Palumbo R; Bernardo A; Riccardi A; Teragni C; Poggi G; Frascaroli M; Amatu A; Montagna B; Sottotetti F; Tagliaferri B; Bernardo G
    Clin Breast Cancer; 2012 Feb; 12(1):30-9. PubMed ID: 22154360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine as palliative therapy in advanced breast cancer.
    Gasco M; Gardin G; Repetto L; Campora E; Rosso R
    Anticancer Res; 1997; 17(2B):1431-3. PubMed ID: 9137510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
    Chan A; Martin M; Untch M; Gil MG; Guillem-Porta V; Wojtukiewicz M; Kellokumpu-Lehtinen P; Sommer HL; Georgoulias V; Battelli N; Pawlicki M; Aubert D; Bourlard T; Gasmi J; Villanova G; Petruzelka L;
    Br J Cancer; 2006 Oct; 95(7):788-93. PubMed ID: 16969343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer.
    Guerrero A; Servitja S; Rodríguez-Lescure A; Calvo L; del Barco S; Quintanar MT; Juárez JI; Gayo J; Llombart A; Tusquets I
    Anticancer Drugs; 2011 Mar; 22(3):283-9. PubMed ID: 21150776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.